Sanovas Awarded Global "Top-50" Start-Up Company
Silicon Valley's "TiE50" Award Hotly Contested by Thousands of Technology Startups Worldwide
SAN RAFAEL, Calif., May 28, 2015 /PRNewswire/ -- Sanovas, Inc., a rapidly growing life science company, has been recognized as one of the Top 50 Start-Up Companies in the World at the Silicon Valley TiE50 Award ceremony.
Logo - http://photos.prnewswire.com/prnh/20150528/219097LOGO
TiE's carefully chosen panel of segment experts with direct domain experience screened 2,716 companies from around the world. Scoring was done on each company's Intellectual Property, Business Model, and Team. This select list was further subjected to a higher level of diligence and screening by the expert panel of judges who are Serial Entrepreneurs, Venture Capitalists, Angel Investors, CEOs, and accomplished Technology Experts. Upon final submission, the scores were locked-in and validated. The short-listed companies were announced as "2015 TiE50 Top Start-ups."
The final 50 were chosen as "The Very Best of the Best". These 2015 TiE50 Winners were then announced at Silicon Valley's TiEcon 2015 award ceremony on May 15. Sanovas was awarded in the presence of a live audience of thousands. See the winners here: http://www.tie50.net/TiE50Awards/
"We are extraordinarily delighted by this substantial recognition," said Larry Gerrans, Chairman, CEO and President of Sanovas. "Sanovas was conceived with the inspiration to advance new standards of cost effective care for billions of patients globally. It is gratifying to be recognized for the contributions we are making on behalf of our fellow citizens across the globe."
The TiE50 track record since its inception shows that more than 9 out of 10 award recipients have attracted significant funding in the billions of dollars. Many of these TiE50 award-winners have since been acquired, merged or gone public.
Sanovas revolutionary, patented products are designed to enable surgeons to access, image, measure, diagnose and treat diseased anatomy in areas of the body that are inaccessible using currently marketed surgical tools. The company is pursuing an expansion in global patient populations, from 750 million addressable patients in existing markets to over 3.1 billion addressable patients in the emerging markets. "These products are designed to provide surgeons with faster, less invasive, lower risk and more cost effective interventional treatments," added Mr. Gerrans.
Sanovas is initially targeting the pulmonary market, which includes treatments for Lung Cancer, COPD, Asthma and Cystic Fibrosis. Future addressable markets include treatment of diseases and disorders of the six major organ systems. Together, these represent a potential $118 billion commercial opportunity in the existing markets alone.
About TiE
TiE is a Global Not-for-Profit network of entrepreneurs and professionals dedicated to the advancement of entrepreneurship. TiE provides a platform for mentoring, networking and education for technology entrepreneurs worldwide. Its global network of 61 chapters are located in most major North American, Asian and European countries and cities with more than 11,500 members across 18 countries.
About Sanovas
At the heart of the Sanovas companies' scientific advances is the miniaturization of tools for minimally invasive surgery, or "M-I-S." Its products extend access beyond current limits, enabling physicians to diagnose and perform therapeutic interventions in spaces as small as one millimeter in diameter that have previously been unreachable.
Contacts:
Steve Goldsmith, Sanovas, 415-729-9391 x1023, Email
Ronald Trahan, APR, Ronald Trahan Associates, 508-359-4005 x108, Email
SOURCE Sanovas
Share this article